Cargando…

Hepatitis C prevalences in the psychiatric setting: Cost-effectiveness of scaling-up screening and direct-acting antiviral therapy

BACKGROUND & AIMS: Patients hospitalised because of mental illness often have risk factors for contracting HCV. Scaling-up HCV screening for all psychiatric inpatients as a case-detection strategy for viral elimination is underexplored. This study aimed to evaluate the cost-effectiveness of scal...

Descripción completa

Detalles Bibliográficos
Autores principales:	Girardin, François, Painter, Chris, Hearmon, Natalie, Eddowes, Lucy, Kaiser, Stefan, Negro, Francesco, Vernaz, Nathalie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8424278/ https://www.ncbi.nlm.nih.gov/pubmed/34522875 http://dx.doi.org/10.1016/j.jhepr.2021.100279

Ejemplares similares

Scaling-up hepatitis C screening and treatment in Swiss outpatient psychiatric settings: A cost-effectiveness analysis
por: Girardin, François, et al.
Publicado: (2022)

Investigating zero transmission of HIV in the MSM population: a UK modelling case study
por: Massey, Katherine, et al.
Publicado: (2023)

Drug Pricing Evolution in Hepatitis C
por: Vernaz, Nathalie, et al.
Publicado: (2016)

Patented Drug Extension Strategies on Healthcare Spending: A Cost-Evaluation Analysis
por: Vernaz, Nathalie, et al.
Publicado: (2013)

Cost-effectiveness of HLA-DQB1/HLA-B pharmacogenetic-guided treatment and blood monitoring in US patients taking clozapine
por: Girardin, François R., et al.
Publicado: (2018)

Psychiatric treatment considerations with direct acting antivirals in hepatitis C
por: Sockalingam, Sanjeev, et al.
Publicado: (2013)

Evaluating psychiatric outcomes associated with direct-acting antiviral treatment in veterans with hepatitis C infection
por: Sackey, Bryan, et al.
Publicado: (2018)

Developing a direct acting, orally available antiviral agent in a pandemic: the evolution of molnupiravir as a potential treatment for COVID-19
por: Painter, George R, et al.
Publicado: (2021)

Minimum Costs for Producing Hepatitis C Direct-Acting Antivirals for Use in Large-Scale Treatment Access Programs in Developing Countries
por: Hill, Andrew, et al.
Publicado: (2014)

Development and validation of the OUTCoV score to predict the risk of hospitalisation among patients with SARS-CoV-2 infection in ambulatory settings: a prospective cohort study
por: Jacquerioz, Frederique, et al.
Publicado: (2021)

Evaluation of oral antipsychotic supplementation of select second-generation long-acting injectable antipsychotics in an acute-care psychiatric setting
por: Alastanos, Jennifer N., et al.
Publicado: (2019)

Electrocardiographic Screening for Prolonged QT Interval to Reduce Sudden Cardiac Death in Psychiatric Patients: A Cost-Effectiveness Analysis
por: Poncet, Antoine, et al.
Publicado: (2015)

Sustained Virologic Response and Costs Associated with Direct-Acting Antivirals for Chronic Hepatitis C Infection in Oklahoma Medicaid
por: Pham, Timothy T., et al.
Publicado: (2018)

Cost‐effectiveness of screening and treatment using direct‐acting antivirals for chronic Hepatitis C virus in a primary care setting in Karachi, Pakistan
por: Mafirakureva, Nyashadzaishe, et al.
Publicado: (2020)

Snapshot of the prescribing practice for the clopidogrel and esomeprazole coprescription and cost evaluation of the application guidelines
por: Vernaz, Nathalie, et al.
Publicado: (2016)

Correction: Electrocardiographic Screening for Prolonged QT Interval to Reduce Sudden Cardiac Death in Psychiatric Patients: A Cost-Effectiveness Analysis
por: Poncet, Antoine, et al.
Publicado: (2015)

Cost-effectiveness of hepatitis C treatment using generic direct-acting antivirals available in India
por: Aggarwal, Rakesh, et al.
Publicado: (2017)

Cost-Effectiveness Analysis of Direct-Acting Antiviral Agents for Occupational Hepatitis C Infections in Germany
por: Runge, Melanie, et al.
Publicado: (2020)

Direct-Acting Antivirals in Chronic Hepatitis C Genotype 4 Infection in Community Care Setting
por: Gayam, Vijay, et al.
Publicado: (2018)

SARS-CoV-2 testing strategy: A comparison of restricted and extended strategies in a Swiss outpatient cohort from the community and hospital employees
por: Baggio, Stéphanie, et al.
Publicado: (2021)

HIV/HCV Antiviral Drug Interactions in the Era of Direct-acting Antivirals
por: Rice, Donald P., et al.
Publicado: (2016)

Cost-effectiveness and budgetary impact of HCV treatment with direct-acting antivirals in India including the risk of reinfection
por: Chaillon, Antoine, et al.
Publicado: (2019)

Association of Direct-Acting Antiviral Therapy for Hepatitis C With After-Treatment Costs Among Medicare Beneficiaries
por: Jung, Jeah, et al.
Publicado: (2020)

Estimating the price at which hepatitis C treatment with direct-acting antivirals would be cost-saving in Japan
por: Zhuo, Yueran, et al.
Publicado: (2020)

Treatment with direct-acting antivirals improves peripheral insulin sensitivity in non-diabetic, lean chronic hepatitis C patients
por: Gastaldi, Giacomo, et al.
Publicado: (2019)

Direct-acting antiviral treatment in real world patients with hepatitis C not associated with psychiatric side effects: a prospective observational study
por: Sundberg, Isak, et al.
Publicado: (2018)

Population-level estimates of hepatitis C reinfection post scale-up of direct-acting antivirals among people who inject drugs
por: Yeung, Alan, et al.
Publicado: (2022)

Translation, validity and reliability of decision style scale in forensic psychiatric setting in Indonesia
por: Raharjanti, Natalia Widiasih, et al.
Publicado: (2022)

Outcomes and Follow-Up after Hepatitis C Eradication with Direct-Acting Antivirals
por: Lynch, Erica Nicola, et al.
Publicado: (2023)

On the Fungus Foot Disease and Its Treatment
por: Eddowes, W.
Publicado: (1867)

Strychnine in Fever
por: Eddowes, U.
Publicado: (1866)

Elephantiasis of Left Leg of Fifteen Years' Duration; Amputation, Only One Vessel Requiring Ligature
por: Eddowes, W.
Publicado: (1866)

Towards supporting greater and lower cost access to direct acting antiviral treatment for hepatitis C for all patients
por: Al-Busafi, Said A., et al.
Publicado: (2017)

Price of a hepatitis C cure: Cost of production and current prices for direct-acting antivirals in 50 countries
por: Barber, Melissa J., et al.
Publicado: (2020)

Cost-Utility Analysis of Direct-Acting Antivirals for Treatment of Chronic Hepatitis C Genotype 1 and 6 in Vietnam
por: Due, Ong The, et al.
Publicado: (2020)

The impact of direct acting antivirals on hepatitis C virus disease burden and associated costs in four european countries
por: Mennini, Francesco S., et al.
Publicado: (2021)

Long-acting antiviral agents for HIV treatment
por: Margolis, David A., et al.
Publicado: (2015)

Influenza Antiviral Subversion: Now the Host Is in on the Act
por: Yepsen, Erin N., et al.
Publicado: (2021)

Mental health clustering and diagnosis in psychiatric in-patients
por: Trevithick, Liam, et al.
Publicado: (2015)

Hepatitis C virus treatment for prevention among people who inject drugs: Modeling treatment scale-up in the age of direct-acting antivirals
por: Martin, Natasha K, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_4gomkp3c0d1sa025h9uigt1uqk